カテゴリー： 世界, 医療/バイオ, 360iResearch

PARP阻害剤薬物療法のグローバル市場（2023-2030）：ニラパリブ、オラパリブ、ルカパリブ

【英語タイトル】PARP Inhibitors Drug Therapy Market by Drug (Niraparib, Olaparib, Rucaparib), Indication (Breast Cancer, Ovarian Cancer, Pancreatic Cancer), Distribution Channel - Global Forecast 2023-2030

360iResearchが出版した調査資料（360i23N190）・商品コード：360i23N190
・発行会社（調査会社）：360iResearch
・発行日：2023年10月
・ページ数：185
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（2～3営業日）
・調査対象地域：グローバル
・産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名利用、印刷可）USD4,949 ⇒換算￥752,248見積依頼/購入/質問フォーム
Enterprise License（企業利用、印刷可）USD8,949 ⇒換算￥1,360,248見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

PARP阻害剤薬物療法の市場規模は2022年に61.8億ドルと推定され、2023年には67.3億ドルに達すると予測され、CAGR 9.12%で、2030年には124.3億ドルに達すると予測されています。
市場細分化とカバー範囲：
この調査レポートは、PARP阻害剤薬物療法市場の包括的な見通しを提供するために、様々なサブ市場を分析し、収益を予測し、各カテゴリの新たな動向を調査しています。

● 薬剤別では、ニラパリブ、オラパリブ、ルカパリブ、タラゾパリブについて調査しています。予測期間中、ニラパリブが大きな市場シェアを占めると予測。
● 適応症別では、乳がん、卵巣がん、膵がん、前立腺がんで調査。予測期間中、前立腺がんが大きなシェアを占めると予測されています。
● 流通チャネル別では、病院薬局、オンライン薬局、小売薬局が調査対象である。予測期間中、病院薬局が大きなシェアを占めると予測されています。
● 地域別では、米州、アジア太平洋地域、欧州・中東・アフリカ地域で調査しています。米州はさらにアルゼンチン、ブラジル、カナダ、メキシコ、米国で調査されています。米国はさらにカリフォルニア、フロリダ、イリノイ、ニューヨーク、オハイオ、ペンシルバニア、テキサスで調査されています。アジア太平洋地域は、オーストラリア、中国、インド、インドネシア、日本、マレーシア、フィリピン、シンガポール、韓国、台湾、タイ、ベトナムで調査されています。ヨーロッパ・中東・アフリカは、デンマーク、エジプト、フィンランド、フランス、ドイツ、イスラエル、イタリア、オランダ、ナイジェリア、ノルウェー、ポーランド、カタール、ロシア、サウジアラビア、南アフリカ、スペイン、スウェーデン、スイス、トルコ、アラブ首長国連邦、イギリスを対象としている。南北アメリカは予測期間中に大きな市場シェアを占めると予測されています。

市場統計：
本レポートでは、7つの主要通貨（ドル、ユーロ、日本円、英ポンド、豪ドル、カナダドル、スイスフラン）の市場規模と予測を掲載しています。本レポートでは、2018年から2021年までを過去年、2022年を基準年、2023年を推定年、2024年から2030年までを予測期間としています。

FPNVポジショニングマトリックス：
FPNVポジショニングマトリックスは、PARP阻害剤薬物療法市場を評価するための不可欠なツールです。事業戦略と製品満足度に関連する主要指標を分析し、企業を包括的に評価する。これにより、ユーザーは特定のニーズに合わせた情報に基づいた意思決定を行うことができます。高度な分析により、企業は4つの象限に分類され、それぞれ成功のレベルが異なります： フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。この洞察に満ちたフレームワークにより、意思決定者は自信を持って市場をナビゲートすることができます。

市場シェア分析：
市場シェア分析は、PARP阻害剤薬物療法市場の企業情報に関する貴重な洞察を掲載しています。全体的な収益、顧客基盤、その他の主要指標に対する影響を評価することで、各社の業績と直面している競争環境について包括的な理解を掲載しています。この分析では、調査期間中の市場シェア獲得、断片化、優位性、業界再編などの競争レベルも明らかにします。

主要企業のプロフィール：
本レポートでは、PARP阻害剤薬物療法市場における最近の重要な動向を掘り下げ、主要企業とその革新的なプロフィールを紹介しています。これには、AbbVie Inc.、Artios Pharma Limited、AstraZeneca PLC、BeiGene, Inc.、Bristol-Myers Squibb Company、Clovis Oncology、GlaxoSmithKline PLC、IMPACT Therapeutics、Jeil Pharmaceuticals Co. Ltd.、Jiangsu Hengrui Pharmaceuticals Company Ltd.、Johnson & Johnson Services, Inc.、Karyopharm Therapeutics、Merck & Co., Inc.、Ono Pharmaceutical Co., Ltd., Pfizer Inc.、Repare Therapeutics, Inc. などの企業が含まれています。

本レポートは、以下の側面に関する貴重な洞察を掲載しています：
1. 市場浸透： 主要企業の市場ダイナミクスと製品に関する包括的な情報を掲載しています。
2. 市場開拓： 新興市場と成熟市場セグメントへの浸透を詳細に分析し、有利な機会を強調します。
3. 市場の多様化： 新製品の発売、未開拓の地域、最近の開発、投資に関する詳細情報。
4. 競合他社の評価とインテリジェンス： 主要企業の市場シェア、戦略、製品、認証、規制当局の承認、特許状況、製造能力を網羅的に評価。
5. 製品開発とイノベーション： 将来の技術、研究開発活動、画期的な製品開発に関する知的洞察。

本レポートは、以下のような主要な質問に対応しています：
1. PARP阻害剤薬物療法市場の市場規模および予測は？
2. PARP阻害剤薬物療法市場で最も高い投資ポテンシャルを持つ製品、セグメント、用途、分野は何か？
3. PARP阻害剤薬物療法市場の機会を特定するための競争戦略的窓は何か？
4. PARP阻害剤薬物療法市場における最新の技術動向と規制の枠組みは？
5. PARP阻害剤薬物療法市場における主要企業の市場シェアは？
6. PARP阻害剤薬物療法市場への参入には、どのような形態や戦略的動きが適しているか？

1. 序論
2. 調査方法
3. エグゼクティブサマリー
4. 市場概要
5. 市場インサイト
6. PARP阻害剤薬物療法の世界市場：薬剤別
7. PARP阻害剤薬物療法の世界市場：疾患別
8. PARP阻害剤薬物療法の世界市場：流通チャネル別
9. アメリカのPARP阻害剤薬物療法市場
10. アジア太平洋のPARP阻害剤薬物療法市場
11. ヨーロッパ、中東/アフリカのPARP阻害剤薬物療法市場
12. 競争状況
13. 競合ポートフォリオ
14. 付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. PARP Inhibitors Drug Therapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancers
5.1.1.2. Growing numbers of clinical trials worldwide
5.1.1.3. Elevation in government approvals for PARP drugs
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Ongoing research and development projects to introduce novel drug therapies
5.1.3.2. Governmental programs to enhance the cancer treatment therapies
5.1.4. Challenges
5.1.4.1. Concerns associated with side effects of drug therapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. PARP Inhibitors Drug Therapy Market, by Drug
6.1. Introduction
6.2. Niraparib
6.3. Olaparib
6.4. Rucaparib
6.5. Talazoparib
7. PARP Inhibitors Drug Therapy Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Ovarian Cancer
7.4. Pancreatic Cancer
7.5. Prostate Cancer
8. PARP Inhibitors Drug Therapy Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas PARP Inhibitors Drug Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific PARP Inhibitors Drug Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Artios Pharma Limited
13.1.3. AstraZeneca PLC
13.1.4. BeiGene, Inc.
13.1.5. Bristol-Myers Squibb Company
13.1.6. Clovis Oncology
13.1.7. GlaxoSmithKline PLC
13.1.8. IMPACT Therapeutics
13.1.9. Jeil Pharmaceuticals Co. Ltd.
13.1.10. Jiangsu Hengrui Pharmaceuticals Company Ltd.
13.1.11. Johnson & Johnson Services, Inc.
13.1.12. Karyopharm Therapeutics
13.1.13. Merck & Co., Inc.
13.1.14. Ono Pharmaceutical Co., Ltd.
13.1.15. Pfizer Inc.
13.1.16. Repare Therapeutics, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
TABLE 3. PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 6. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 11. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 30. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 33. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 47. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 50. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 56. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 74. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 84. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 87. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 90. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 93. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 96. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 102. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 111. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 114. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 117. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 129. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 138. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 147. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2022
TABLE 148. PARP INHIBITORS DRUG THERAPY MARKET LICENSE & PRICING


★調査レポート[PARP阻害剤薬物療法のグローバル市場（2023-2030）：ニラパリブ、オラパリブ、ルカパリブ] (コード：360i23N190)販売に関する免責事項を必ずご確認ください。
★調査レポート[PARP阻害剤薬物療法のグローバル市場（2023-2030）：ニラパリブ、オラパリブ、ルカパリブ]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の卵巣がん治療薬市場（2023-2030）：治療クラス別（PARP、PD-L1、血管新生阻害剤）、治療法別、最終用途別、地域別
  • 放射線腫瘍のグローバル市場（2023-2030）：ブラキセラピー、外部照射療法、ラジオアイソトープ療法
  • 副腎コルチコステロイド阻害剤のグローバル市場（2023-2030）：アミノグルテチミド、レボケトコナゾール、メチラポン
  • 膵臓がん治療薬のグローバル市場（2023-2030）：内分泌膵臓がん、外分泌膵臓がん
  • 循環腫瘍細胞のグローバル市場（2023-2030）：血液、骨髄
  • 抗体薬物複合体のグローバル市場（2023-2030）：CD30抗体、ErbB2抗体
  • 肉腫治療薬のグローバル市場（2023-2030）：血管肉腫、軟骨肉腫、皮膚線維肉腫
  • 特殊医薬品流通のグローバル市場（2023-2030）：エイズ、血友病、多発性硬化症
  • がん/腫瘍プロファイリングのグローバル市場（2023-2030）：イムノアッセイ、インサイチュハイブリダイゼーション、質量分析
  • 経皮薬物送達システム（TDDS）のグローバル市場（2023-2030）：経皮パッチ、経皮半固形剤

    • ◆H&Iグローバルリサーチのお客様（例）◆